<DOC>
	<DOCNO>NCT00209612</DOCNO>
	<brief_summary>A phase I/II study conduct determine maximum-tolerated dose ( MTD ) , dose-limiting toxicity ( DLT ) , efficacy combination chemotherapy use CPT-11 Paclitaxel pre-treated patient metastatic gastric cancer . The usefulness regimen evaluate response rate , median survival time , progression free survival .</brief_summary>
	<brief_title>Phase I/II Study Paclitaxel Plus CPT-11 Pts . With 2nd Line Chemotherapy Inoperable Recurrent GC .</brief_title>
	<detailed_description>Patients pre-treated measurable metastatic gastric cancer include trial . Patients receive combination chemotherapy repeat every 28 day progression disease . Starting dose ( dose level 1 ) CPT-11 80 mg/m2 day 1 15 , Paclitaxel 60 mg/m2 day 1 15 . DLT define follow ( accord NCI-CTC version 2.0 ) ; Grade 4 neutropenia , thrombocytopenia ( ≥25000 ) , Grade 3 neutropenia accompany fever ( &gt; 38℃ ) , Grade 3 non-hematological toxicity ( except nausea , vomit , appetite loss , general fatigue , alopecia ) . Maximal Tolerated Dose ( MTD ) determine incidence critical toxicity exceed 50 % certain dose level . Response rate calculate accord RECIST criterion .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm metastatic recurrent gastric cancer prior treatment advanced disease . Patients receive 1cycle cancer therapy ( radiotherapy , chemotherapy chemoradiotherapy ) give &gt; 4 week prior begin study therapy At least one measurable lesion accord RECIST criterion . Minimum indicator lesion size : &gt; 10 mm measure spiral CT &gt; 20mm measure conventional technique ( Except Phase I set ) . Patients age 20 75 year , inclusive , time acquisition inform consent Patients performance status ( ECOG ) 0 2 Abnormal hematologic value ( WBC ≥ 3.5 x 109/L , Hemoglobin ≥ 9.0g/dl , platelet count ≥ 100 x 109/L ) Serum cleatinine ≤ 1.5mg/dl Serum bilirubin ≤ 1.5mg/dl . ALT , AST ≤ 2.0 x upper normal limit ( ≤ 3 x upper normal limit case liver metastasis ) Normal ECG Life expectancy ≥ 3 month Patients give write informed consent participate study Patients active multiple cancer ; even multiple cancer metachronous , diseasefree period le 5 year ( exclude cancer situ skin cancer ) ( Except Phase I set ) Serious , uncontrolled , concurrent infection ( ) illness ( es ) Patients serious concurrent complication ( heart disease , Intestinal pneumonia ) Patients Liver cirrhosis Patients fresh hemorrhage gastrointestinal tract Patients poorly control diabetes treat continuous use insulin Patients concurrent psychiatric disease psychotic symptom , judge difficulty participate study Patients retention body fluid ( pleural effusion , ascites , pericardial effusion ) necessitate treatment Patients diarrhea ( watery stool ) Patients infection , intestinal palsy intestinal occlusion Patients brain metastasis Patients Gilbert syndrome Patients experience serious drug allergy past Patients pregnant lactate hope become pregnant study period Patients prior Taxan ( Paclitaxel , Docetaxel ) CPT11 treatment Patients neuropathy ≥ grade 2 Others , patient judge investigator subinvestigator inappropriate subject</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>